Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT07668739
Starting soon Phase 4

Efficacy of Verciguat in TR and RV Failure

NCT07668739 · tracked via the Priya Life Science South Korea tracker
Sponsor
Daejeon St. Mary's hospital
Phase
Phase 4
Started
2026-07-01
Last updated
2026-06-25

Condition(s) studied

HFrEFTricuspid Regurgitation (TR)

Investigational drug(s) / intervention(s)

Vericiguat →

Vericiguat: Participants will start vericiguat at 2.5 mg once daily, and the dose will be gradually uptitration every 2 weeks to a target dose of 10 mg once daily, depending on tolerability.

Study summary

The goal of this clinical trial is to learn if the drug vericiguat works to improve right heart function in patients with worsening heart failure who have reduced left ventricular function. It will also examine the effects of the drug on tricuspid regurgitation (TR) and overall clinical outcomes.

The main questions it aims to answer are:

Does vericiguat improve right ventricular (RV) function and reduce tricuspid regurgitation (TR)? Does vericiguat reduce the risk of major adverse cardiovascular events (MACE), such as heart failure hospitalizations and cardiovascular death? Does vericiguat improve participants' exercise capacity, quality of life, and renal function?

Researchers have previously seen the benefits of vericiguat in the large-scale VICTORIA trial for worsening heart failure, and it is hypothesized that improvements in right heart function play a key role. This study aims to confirm these specific benefits.

Participants will:

Take vericiguat as prescribed during the study period. Undergo echocardiograms at enrollment and at 9 months to assess right heart function.

Complete questionnaires (KCCQ-12) and walking tests (6MWT) to evaluate quality of life and exercise capacity.

Provide blood samples to monitor NTproBNP levels and renal function (creatinine).

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age more than 19 years old 2. right ventricular malfunction confirmed with EKG data or cardiac MRI 3. chronic heart failure with LVEF\<45% 4. Patients Who administrated standard treatment of Heart Failur for over the 4 weeks 5. NTproBNP \>1000, NTproBNP \>1600 with atrial fibrillation or The patient who recently experienced worsening heart failure(Recent hospitalization for worsening heart failure or outpatient administration of intravenous diuretics) 6. Tricuspid regurgitation of greater than moderate severity was confirmed by echocardiogram 7. Subject who provided voluntary informed consent to participate in the study 8. Patients who have not been administered vericiguat within the last 6 months Exclusion Criteria: 1. Patients with a systolic blood pressure (SBP) \< 100 mmHg 2. Patients currently treated with other sGC stimulators (including vericiguat) or phosphodiesterase-5 (PDE5) inhibitors 3. Moderate-to-severe right ventricular (RV) failure requiring surgical intervention 4. Patients who are currently pregnant or of childbearing potential

Primary outcome measure(s)

  • NTproBNP — NTproBNP will be assessed from enrollment to the end of treatment at baseline, 3 and 9 months.
  • Echocardiographic RV function parameters — From enrollment to the end of treatment at baseline and 9 months
    RVSP, RV volume, TAPSE, RV strain/PAP, TR grade

Trial sites (1)

FacilityCityRegionStatus
Daejeon St.Mary's Hospital Daejeon South Korea

Other trials for the same condition

Efficacy of Early Rhythm Control in AF With TR Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07668739 on ClinicalTrials.gov ↗ ← All trials in South Korea